{"links":{"html":"https://www.erudio.com/reports/libertas-nct05884398","json":"https://www.erudio.com/reports/libertas-nct05884398.json","markdown":"https://www.erudio.com/reports/libertas-nct05884398.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"libertas-05884398"}},"request":"https://www.erudio.com/contact?report=libertas-05884398"},"offer":{"cited_commentary_sources":56,"verified_hcp_statements":813,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization; never for outreach to or targeting of clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":43,"optional":true,"price_per_verified_person_usd":15,"price_usd":645,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"libertas-nct05884398"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=libertas-05884398","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/libertas-nct05884398","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-03T09:46:04.436116Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":4,"title":"Primary endpoint: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months"},{"claim_count":24,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":20,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":26,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":18,"title":"The comparison"},{"claim_count":40,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":10,"title":"Safety and tolerability"},{"claim_count":14,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":10,"title":"Design and conduct"},{"claim_count":28,"coverage":"discussed","id":"A1","source_count":10,"title":"Acting before prospective stopping evidence"},{"claim_count":43,"coverage":"discussed","id":"A2","source_count":7,"title":"Historical and adjacent interruption evidence"},{"claim_count":28,"coverage":"discussed","id":"A3","source_count":13,"title":"Response depth, discordant progression and restart decisions"},{"claim_count":50,"coverage":"discussed","id":"A4","source_count":6,"title":"Local treatment as an alternative or addition around systemic-treatment reduction"},{"claim_count":53,"coverage":"discussed","id":"A5","source_count":10,"title":"Initial doublet treatment, selective intensification, prognostic work-up and reasons to withhold treatment"},{"claim_count":44,"coverage":"discussed","id":"A6","source_count":8,"title":"Molecular and imaging work-up for individualized intensity"},{"claim_count":27,"coverage":"discussed","id":"A7","source_count":7,"title":"Patient willingness, reassurance and the experience of uncertainty"},{"claim_count":40,"coverage":"discussed","id":"A8","source_count":7,"title":"Affordability, coordinated care and patient support"},{"claim_count":18,"coverage":"discussed","id":"A9","source_count":14,"title":"Study reception, inclusive participation and sponsorship"}],"counts":{"cited_clinicians":39,"cited_clinicians_by_role":{"physician":18,"physician, Medical oncology":12,"physician, Radiation oncology":3,"physician, Surgical oncology":1,"physician, Urology":4,"physician_assistant":1},"cited_physicians":38,"cited_sources":57,"claims_by_expression_type":{"comparison":41,"experience":75,"interpretation":158,"opinion":300,"primary_context":2,"question":65,"restatement":92,"uncertainty":33,"unspecified":47},"claims_by_kind":{"counterview":2,"protocol_statement":1,"source_observation":810},"clinician_statements":423,"evidence_units":685,"findings":12,"organisational_accounts":4,"people_cited":50,"people_identity_verified":43,"people_total":50,"screened_sources":92,"verified_claims":813},"findings_index":[{"id":"F1","structure":{"claims":64,"claims_by_group":{"comparisons":0,"experience":12,"questions":12,"restated":6,"views":34},"has_counterview":true,"limitations":2,"links":{"context":12,"support":81},"ma_question":true,"named_voices":13,"passages":59,"sources":16,"sources_by_kind":{"commentary":5,"media":11}},"title":"Whether selective treatment breaks are acceptable before prospective stopping evidence"},{"id":"F2","structure":{"claims":48,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":6,"views":37},"has_counterview":true,"limitations":2,"links":{"context":4,"support":51},"ma_question":true,"named_voices":19,"passages":38,"sources":18,"sources_by_kind":{"commentary":6,"media":12}},"title":"Clinicians emphasize deep PSA response; whether PSA alone can guide stopping remains open"},{"id":"F3","structure":{"claims":64,"claims_by_group":{"comparisons":4,"experience":7,"questions":12,"restated":20,"views":21},"has_counterview":true,"limitations":2,"links":{"context":3,"support":68},"ma_question":true,"named_voices":26,"passages":53,"sources":21,"sources_by_kind":{"commentary":7,"media":14}},"title":"Whether ADT withdrawal alone meets patients' goals—and how it differs from stopping both drugs"},{"id":"F4","structure":{"claims":53,"claims_by_group":{"comparisons":4,"experience":3,"questions":7,"restated":9,"views":30},"has_counterview":true,"limitations":2,"links":{"context":11,"support":59},"ma_question":true,"named_voices":16,"passages":37,"sources":15,"sources_by_kind":{"commentary":4,"media":11}},"title":"Clinicians favor selective stopping discussions in lower-burden disease, with high-risk and competing-risk qualifications"},{"id":"F5","structure":{"claims":74,"claims_by_group":{"comparisons":7,"experience":3,"questions":6,"restated":21,"views":37},"has_counterview":true,"limitations":2,"links":{"context":13,"support":98},"ma_question":true,"named_voices":12,"passages":70,"sources":13,"sources_by_kind":{"commentary":4,"media":9}},"title":"Speakers find interruption precedents informative but qualify extrapolation across studies"},{"id":"F6","structure":{"claims":117,"claims_by_group":{"comparisons":4,"experience":10,"questions":18,"restated":22,"views":63},"has_counterview":true,"limitations":4,"links":{"context":37,"support":160},"ma_question":true,"named_voices":14,"passages":124,"sources":9,"sources_by_kind":{"commentary":2,"media":7}},"title":"Speakers see an ADT-sparing role for local treatment but question repeated lesion-only management"},{"id":"F7","structure":{"claims":89,"claims_by_group":{"comparisons":10,"experience":4,"questions":3,"restated":15,"views":57},"has_counterview":true,"limitations":4,"links":{"context":13,"support":123},"ma_question":true,"named_voices":14,"passages":95,"sources":12,"sources_by_kind":{"media":12}},"title":"Clinicians favor an ARPI doublet over routine ADT alone, while preserving selective non-intensification and observation"},{"id":"F8","structure":{"claims":90,"claims_by_group":{"comparisons":8,"experience":9,"questions":10,"restated":6,"views":57},"has_counterview":true,"limitations":4,"links":{"context":10,"support":115},"ma_question":true,"named_voices":14,"passages":86,"sources":15,"sources_by_kind":{"commentary":2,"media":13}},"title":"Whether and when docetaxel adds benefit beyond ADT–ARPI in response-adapted mHSPC care"},{"id":"F9","structure":{"claims":61,"claims_by_group":{"comparisons":2,"experience":5,"questions":5,"restated":6,"views":43},"has_counterview":true,"limitations":2,"links":{"context":5,"support":69},"ma_question":true,"named_voices":9,"passages":45,"sources":8,"sources_by_kind":{"media":8}},"title":"Clinicians seek molecular and imaging work-up to refine treatment intensity beyond PSA or lesion counts"},{"id":"F10","structure":{"claims":90,"claims_by_group":{"comparisons":1,"experience":17,"questions":14,"restated":19,"views":39},"has_counterview":true,"limitations":3,"links":{"context":15,"support":106},"ma_question":true,"named_voices":23,"passages":83,"sources":17,"sources_by_kind":{"commentary":4,"media":13}},"title":"Clinicians weigh treatment burden, testosterone recovery and symptom attribution—not simply time off medication"},{"id":"F11","structure":{"claims":43,"claims_by_group":{"comparisons":0,"experience":4,"questions":7,"restated":7,"views":25},"has_counterview":true,"limitations":1,"links":{"context":6,"support":56},"ma_question":true,"named_voices":9,"passages":53,"sources":7,"sources_by_kind":{"media":7}},"title":"Speakers make access, specialist competence and patient support practical conditions for treatment plans"},{"id":"F12","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":17},"has_counterview":false,"limitations":2,"links":{"context":0,"support":18},"ma_question":true,"named_voices":7,"passages":18,"sources":14,"sources_by_kind":{"commentary":14}},"title":"Contributors welcome LIBERTAS research and inclusion; one clinician defends its industry sponsorship"}],"medical_affairs_question":"Which patients, stopping strategy, monitoring requirements and uncertainties should an ADT-sparing discussion make explicit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Acting now versus waiting: selective practice, unresolved safety"},{"id":"section-2","level":2,"title":"Whether deep PSA response can guide stopping—and what PSA misses"},{"id":"section-3","level":2,"title":"Which component stops—and whose treatment goals are met?"},{"id":"section-4","level":2,"title":"Who might stop treatment, and who might need continued suppression?"},{"id":"section-5","level":2,"title":"What can interruption precedents establish for intermittent doublets?"},{"id":"section-6","level":2,"title":"What should local treatment achieve when systemic therapy might be delayed or stopped?"},{"id":"section-7","level":2,"title":"Where do clinicians limit their preference for initial doublets?"},{"id":"section-8","level":2,"title":"Does triplet evidence answer the comparison with an ADT–ARPI doublet?"},{"id":"section-9","level":3,"title":"Who might warrant more treatment?"},{"id":"section-10","level":3,"title":"Intensify first to stop later—or adapt after response?"},{"id":"section-11","level":3,"title":"Which alternatives and patient features enter doublet–triplet decisions?"},{"id":"section-12","level":2,"title":"Could molecular and imaging measures improve response-guided selection?"},{"id":"section-13","level":3,"title":"What information should enter the decision?"},{"id":"section-14","level":3,"title":"How might molecular biology alter reassurance from a low lesion count?"},{"id":"section-15","level":3,"title":"Which molecular tests are usable, and what do results mean for families?"},{"id":"section-16","level":2,"title":"What do treatment breaks mean for testosterone recovery, symptoms and restarting?"},{"id":"section-17","level":3,"title":"Which component is responsible for symptoms, and when do clinicians interrupt or switch it?"},{"id":"section-18","level":3,"title":"How do clinicians manage symptom, bone and cardiac risks during hormonal treatment?"},{"id":"section-19","level":2,"title":"How do access, clinical expertise and patient support shape treatment feasibility?"},{"id":"section-20","level":2,"title":"How do contributors describe the research question, inclusion goals and industry sponsorship?"},{"id":"section-21","level":3,"title":"Scope of these readings"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F10","shared_claims":3}],"id":"T2","label":"Primary endpoint: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months"},{"findings":[{"id":"F2","shared_claims":16},{"id":"F3","shared_claims":2},{"id":"F10","shared_claims":6}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F4","shared_claims":18},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":23},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F7","shared_claims":2},{"id":"F8","shared_claims":2},{"id":"F10","shared_claims":35}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":9},{"id":"F5","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-03T09:46:04.436116Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-03T10:04:52Z","record_hash":"e0fa9583124da1583dec9aaae85319349ec4c8ccabc7084d0b130a6eac4da496","release_hash":"dce4f2d465ab2039a0d01eb7424ec7e05cc4963a48e4487cb5bff3a183eba639","report_id":"erudio-nct05884398","run_id":"7086429b-a218-4bcc-bd68-63a91ac965f9","schema_version":"5.0","slug":"libertas-05884398","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"LIBERTAS tests intermittent versus continued androgen-deprivation therapy (ADT) with apalutamide after PSA response in metastatic castration-sensitive prostate cancer; selective breaks before prospective stopping evidence remain contested. The report cites 38 physicians, including 12 medical oncologists, and one physician assistant; a medical oncologist reports co-chairing LIBERTAS. Whether PSA alone can guide stopping remains open, alongside questions about treatment burden and testosterone recovery. Which patients, stopping plans, monitoring requirements and uncertainties should an ADT-sparing discussion make explicit?","meta_description":"92 sources screened · 813 verified statements (423 from clinicians verified by NPI or staff page) from 57 sources · 12 findings. Updated Nov 3, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-b30ca5c5ef90f10da0ef"],"id":"F2","paraphrase":"A radiation oncologist on X asked how treatment-reduction trials using PSA thresholds, including LIBERTAS and EORTC De-escalate, should be designed.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"unavailable"},"source_channel":"x_thread","source_date":"2024-03-13","title":"Clinicians emphasize deep PSA response; whether PSA alone can guide stopping remains open"},{"cited_claim_ids":["claim-781cc1e7736abc8ccbfe"],"id":"F3","paraphrase":"A contributor on X asked whether LIBERTAS had considered broader quality-of-life measurement among its endpoints.","publication_caveats":["The contributor's clinical role is not stated in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":{"reason":"The thread includes posts dated 2023-06-26, 2023-06-27 and 2023-06-28; the individual question's publication date is not specified.","status":"unavailable"},"title":"Whether ADT withdrawal alone meets patients' goals—and how it differs from stopping both drugs"}]},"publication":{"approved_at":"2026-11-03T10:04:52Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":92},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a view on manufacturer-attributed guidance for managing apalutamide-associated rash with antihistamines and topical corticosteroids.","Not yet captured in this edition: a view on genetic testing and treatment selection for aggressive management of high-volume metastatic castration-sensitive prostate cancer.","Not yet captured in this edition: a view on counseling, assessment, dose reduction and discontinuation for apalutamide-associated rash.","Not yet captured in this edition: a view on apalutamide rash management and treatment discontinuation in metastatic castration-sensitive prostate cancer.","Not yet captured in this edition: a question about stopping ADT after response to apalutamide plus ADT while preserving disease control and reducing side effects.","Not yet captured in this edition: a view on treatment de-escalation and quality of life in responding metastatic hormone-sensitive prostate cancer.","Not yet captured in this edition: a view on genetic testing and initial treatment selection in synchronous high-volume metastatic castration-sensitive prostate cancer.","Not yet captured in this edition: a view on rash counseling, treatment interruption, assessment, dose reduction, discontinuation and severity grading during apalutamide treatment.","Not yet captured in this edition: a view on relapse timing as a guide to selecting patients for metastasis-directed therapy.","Not yet captured in this edition: a view on grouping nearby metastatic nodes when selecting local treatment to enable time off ADT.","Not yet captured in this edition: a view on manufacturer guidance for antihistamines and topical corticosteroids to manage apalutamide-associated rash.","Not yet captured in this edition: a view on potentially short-lived treatment sensitivity when weighing treatment intensity in metastatic hormone-sensitive prostate cancer.","Not yet captured in this edition: a view on androgen-receptor pathway intensification versus ADT monotherapy in metastatic castration-sensitive prostate cancer.","136 passages in 60 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","650 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 37 sources about other trials or topics are not included.","Repeated posts, reposts and copies of recordings do not establish additional independent endorsements. Where copies assign the same words to different people, the report keeps those words unnamed and does not count them as separate agreement.","No full protocol or exact-trial results publication was available. Spoken descriptions of treatment allocation sometimes differ, and early PSA or symptom observations do not establish the randomized effects of intermittent versus continued ADT.","Historical intermittent-ADT studies, EMBARK, ADREAM and other response-guided studies involve different settings, treatment components or stopping rules. Their findings remain attributed supporting arguments, not LIBERTAS results.","Clinical anecdotes, reported conference votes and hypothetical patient examples do not establish comparative efficacy, safety or the frequency of a practice. Some testosterone-replacement anecdotes do not specify the patient's disease stage.","Trial involvement and company relationships are described as the sources describe them. Those perspectives are not presented as independent validation, and research identity does not add evidentiary weight.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Reimbursement interpretations, affordability mechanisms and practice descriptions are local and time-specific. They are not confirmation of current coverage rules, and statements made at different times do not by themselves establish a change of mind.","Parts of the funding discussion and some practical treatment questions were not fully assessed, so the range of arguments supporting or challenging those views may be understated."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":12,"publication":0,"registry":1,"regulatory":0,"x_thread":34,"x_video":0,"youtube":9},"by_evidence_role":{"commentary":56,"methods":1},"count":57,"evidence_window":{"end":"2026-11-01","start":"2023-06-24"},"retrieval_snapshot":"2026-11-03T02:33:52.663050Z","timeline":[{"count":2,"week":"2023-W25"},{"count":4,"week":"2023-W26"},{"count":1,"week":"2023-W27"},{"count":2,"week":"2023-W29"},{"count":2,"week":"2023-W30"},{"count":1,"week":"2023-W44"},{"count":2,"week":"2023-W46"},{"count":2,"week":"2024-W04"},{"count":2,"week":"2024-W06"},{"count":1,"week":"2024-W11"},{"count":1,"week":"2024-W15"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W30"},{"count":2,"week":"2024-W46"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W14"},{"count":2,"week":"2025-W18"},{"count":1,"week":"2025-W19"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W45"},{"count":2,"week":"2025-W46"},{"count":2,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W09"},{"count":2,"week":"2026-W18"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05884398:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05884398:context","quote_policy":"short_quote_link_out"},{"id":"openfda:d1cda4f7-cb33-46ea-b9ac-431f6452b1a5:20260702","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-miczfsfixolk42l7343z3bpd-3l4jmhs27iv2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mmq2caobcgxv5mmlcomg5fpr-3mn3ybh6mlq2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mzlu6dkbduz3toqkexcuo3yx-3mpojiureif27","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:36d74b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3e7ccd","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4a0431","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:58093d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5fa930","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7ac8f7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fe422","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b8f858","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bd15ba","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c5a91d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d91d33","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e91200","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:efde7d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1669448421193785344:c305c116-4ccf-48d3-b8be-97756d5e1522","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672446285306273792:6f2468bb-f74c-405d-a9aa-56ee8dd4a125","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672598370014183427:553e3288-b7f3-44ee-8449-9b7553436c17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1673381278387781646:09e75999-8016-4073-9787-78d3d9ceb9c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1673384380176146437:084b7e46-ca5d-4f53-9e21-c27b4ce68938","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1673519621679247361:0f52bd5c-38f4-44cf-a2ea-d388c0aeee6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1673571987074207744:41e348de-4601-45e1-b9a5-b9cbae7a704a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1676906618699796481:fa1c416f-4ff1-415a-81ab-94912ab3a0f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1681710934077603847:93aa6101-5be4-44b6-bade-41586b8c2574","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682442817313079296:eae99ad5-7fc4-48fc-8814-7427e7f27e26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1684468006968250369:96e3a60a-c26e-4b6b-b14f-b0645478e895","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1684536402849976321:ec806fdf-09e7-482e-b8e2-75656a019899","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702437097687134470:f86793ee-3c56-4692-905c-b1c4a6516d16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702443772540313628:de9c5e01-0645-4c27-a565-eb6164f8ce03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1719736040552833255:591509e1-d81b-4d65-8077-6256ad8f1eef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725569945730240894:f0c27630-6669-45c4-8131-353c35ffac00","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725613331992420619:f9c1a409-fa87-4ec1-a512-051ce9f186e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750588428293685326:87edffa5-a217-4595-ba96-9d527e3e5f47","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750930251536879853:67d7aa39-a0ad-469f-8caa-cfffe6dcbacc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750998384972849290:800913c1-2709-4f60-b910-ed6a789ffe56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754905325847621886:084eabe0-be0a-41df-a7a5-59f1b603ed62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1756140458844287120:29af1650-c988-4eb0-9385-99bb11388877","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1766501731364381046:3d6e62c4-17e4-4c6a-aa16-8a375cf3c5f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1767907180697579784:08a6f18d-3113-46af-8fc0-ea9945650af7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1774822807924249004:ed6fa95d-5b17-4275-9f33-15e50b18f461","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1778807823842873827:63ebf3a5-8d05-484a-8022-3eef4a89032e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1779168467692007838:87aedd37-7e13-4cb9-a19c-69f7b70972c9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783756086576660779:c52671ad-7123-4536-a109-751e776e67a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783756355095892277:7c4379a5-4783-4af2-97ca-a86ba0a4c69e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783758094163488885:fee624e5-fc6f-40af-ad32-86a9fbbd4db7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1785685698533527622:47d7accf-57c7-4701-9a05-822a24f7a5f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797651991931363468:1bc283bd-e640-465b-b560-7c4b2f753a94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1807798851530559801:0971ea6d-e79e-4a9a-b54d-08ed52f0798e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1810519278904381749:1aaecffe-3174-4c08-9713-7678d3f94caa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1819032876060492068:94a13dfd-1c4b-4164-841c-c6651940f8fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1861845800474779687:303930c8-68cf-48aa-9b13-1b5c22e2d75e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884416778433917424:ce3f3e86-9521-488d-87f8-4b913bec631e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1889140339048608235:a99f56ef-c23e-46f3-b815-bf7dbaa45428","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1891539853164106009:5e36fcc7-18c1-46f5-8d1d-8ff7cb01da5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1910309333943939155:5af5f8c0-c0ac-45c1-ae1a-5a3b3d5cf08b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920456180196897265:42bc946e-0528-45e5-ad4c-f5e3e8e8e569","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933139757380366354:f3a920b8-1226-4463-8c8e-00a7be86edb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940364285470732585:a5592cb5-29dc-452c-a0ca-baebda680e95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940749902155231534:0c03ff51-0119-49dd-ae5d-c38e490ae1f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1950627941169188924:9f1b8bab-a8c4-4acd-ba22-cd614eaec6c0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1953433478881542610:dfa95a7d-6b8a-418d-8bd8-4ab8d9299920","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957444116553330743:e11d76d0-ae98-4d70-b45e-19b247c4ec55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979752534446162254:19032c0d-5547-45db-9e15-7c75fd3614f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979986035363746166:be6455a6-83e5-4ed1-b2cb-e1ff6f529280","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1984248975180853318:423073fd-9498-4046-8090-29d5c15abd16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989571896061432094:e0f7361a-8ce6-4e7b-9d6c-cb434ad72ed2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989572605272006888:f0a395ac-b3eb-47fd-a65c-eae6b2f42bd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1996900401761730653:2b4f8f00-2176-4cba-a154-9340495252e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027090818323128393:872136f6-8b84-4a3d-b4f8-54636b56f86d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027168148756042038:0bf84c09-e76c-4e97-93dc-3b7a1c1697b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032547310253592768:8e4d8ca5-a545-4921-90e7-90c8702fc537","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049413288488837330:e8bdf0ae-5b9a-492c-8c3d-760b26421a59","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050129506078224596:1379de27-08d7-419e-ba1b-afed1a589c40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050130169877164297:c14c74c0-5985-4b15-8442-8226c21733c0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058168621080175025:c8187ede-766a-4e7f-bf3f-6cb40f19a5d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060834326275625296:8bb5064d-88d8-4893-b130-ae241be312c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061431322946490550:10463f53-a969-4a1e-a63d-b79288fdf8e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061452507394474191:de8aa670-e891-4b9b-a5bf-38e956695898","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113579186996551684:36fee18f-b2ec-4afd-ae32-16ac737777de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113600218708992199:5fd9d011-d5d6-480d-915e-0cf22be9d57e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113654232330936393:3b2aac48-1baa-42e5-899d-bbb212352688","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114641569592791472:62acdd24-a277-4c89-990a-28bfcd4fab00","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0XfrF6V1Kro","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5aRsPj4xApg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5f4xfi4JahE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ChH2XbCTYag","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JkrvmKuY48U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QSLW8l2z028","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:VOgDzK4-PNY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jnab5Lr_D4I","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pJAEEsHEUwQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":13,"publication":0,"registry":0,"regulatory":0,"x_thread":67,"x_video":0,"youtube":9},"by_evidence_role":{"commentary":92},"count":92,"evidence_window":{"end":"2026-11-01","start":"2023-06-15"},"retrieval_snapshot":"2026-11-03T02:33:52.663050Z","timeline":[{"count":1,"week":"2023-W24"},{"count":2,"week":"2023-W25"},{"count":4,"week":"2023-W26"},{"count":1,"week":"2023-W27"},{"count":2,"week":"2023-W29"},{"count":2,"week":"2023-W30"},{"count":2,"week":"2023-W37"},{"count":1,"week":"2023-W44"},{"count":2,"week":"2023-W46"},{"count":3,"week":"2024-W04"},{"count":3,"week":"2024-W06"},{"count":1,"week":"2024-W10"},{"count":1,"week":"2024-W11"},{"count":1,"week":"2024-W14"},{"count":2,"week":"2024-W15"},{"count":3,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W30"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W38"},{"count":2,"week":"2024-W46"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W14"},{"count":1,"week":"2025-W15"},{"count":2,"week":"2025-W18"},{"count":2,"week":"2025-W19"},{"count":1,"week":"2025-W20"},{"count":2,"week":"2025-W24"},{"count":1,"week":"2025-W25"},{"count":2,"week":"2025-W27"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W32"},{"count":1,"week":"2025-W34"},{"count":2,"week":"2025-W42"},{"count":2,"week":"2025-W44"},{"count":1,"week":"2025-W45"},{"count":2,"week":"2025-W46"},{"count":2,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W11"},{"count":3,"week":"2026-W18"},{"count":1,"week":"2026-W21"},{"count":2,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":3,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: apalutamide","status":"unmapped"},{"reason":"Unmapped registry intervention: androgen-deprivation therapy (adt)","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Metastatic Castrate-sensitive Prostate Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"LIBERTAS","aliases":["LIBERTAS","A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)"],"brief_title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Castrate-sensitive Prostate Cancer"],"display_condition":"metastatic castration-sensitive prostate cancer","display_interventions":[["apalutamide"]],"enrollment":{"count":420,"type":"ACTUAL"},"interventions":[{"name":"Apalutamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Androgen-deprivation Therapy (ADT)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05884398","official_title":"A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-10-12","type":"ESTIMATED"},"primary_endpoints":[{"description":"rPFS is defined as the duration from the date of randomization to the date of first documentation of confirmed radiographic progressive disease or death due to any cause, whichever occurs first. rPFS will be assessed by investigators using conventional imaging (computed tomography \\[CT\\]/magnetic resonance imaging \\[MRI\\] and 99mTc bone scans).","measure":"Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)","timeFrame":"From randomization (Day 1 of Cycle 7) up to 18 months"},{"description":"Severity adjusted hot flash score will be calculated from the hot flash diary which will be daily filled by the participants.","measure":"Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months","timeFrame":"From randomization (Day 1 of Cycle 7) up to 18 months"}],"registered_date":{"date":"2023-06-01","type":"ACTUAL"},"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT05884398","short_name":"LIBERTAS","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2023-08-31","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CR109327","type":"sponsor_study_id"},{"domain":"Janssen Research & Development, LLC","id":"56021927PCR3020","type":"other"},{"domain":"EUCT number","id":"2022-502686-24-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}